Is Exelixis a US company?
Yes, Exelixis is a U.S.-based oncology biopharmaceutical company [1.2.1]. Founded in 1994 and headquartered in Alameda, California, its primary commercial and organizational operations are centered within the United States [1.2.1]. While it maintains a global footprint through international partnerships—reaching markets outside the U.S. mainly by collaborating with firms like Ipsen and Takeda—its core business model and direct commercial infrastructure are focused on the U.S. oncology market [1.2.1].
Related FAQs
Exelon Corporation, one of the largest utility companies in the United States, holds a generally stable reputation as a reliable provider of electricity to millions of customers.
As of July 2026, Exelixis (EXEL) maintains a "Buy" consensus rating among analysts. The company's stock has demonstrated a strong multi-year performance record, supported by consistent revenue and cash flow from its oncology treatments.
Whether Exelixis (EXEL) is a good stock to buy is a decision that should be based on your personal investment objectives and risk appetite.
Based on the consensus of 14 analysts as of July 24, 2026, Exelixis (EXEL) holds a "Buy" rating. This professional sentiment is driven by the company's historical earnings performance and its role in the biotechnology sector.
Yes, Exelixis has demonstrated strong commercial performance and financial health, largely driven by its oncology drug Cabometyx [1.1.1].